ERG and prostate carcinoma: Androgen treatment of ERG-positive and ERG-negative cells, combined with chromatin immunoprecipitation sequencing, linked sarcosine pathway activation to the androgen receptor and ERG genes, which are key mediators in prostate cancer progression.